61 search results for: symposium

expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min

Dermatology

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

Infographic

The Burden of AD: More Than Skin Deep

5 min

Dermatology

Learn how the multidimensional, cumulative burdens of atopic dermatitis extend beyond the skin and across multiple organ systems, manifesting as atopic and non-atopic comorbidities. Even when an individual is performing well in spite of these burdens, they may still have significant life course impairment due to the cumulative impact of the disease.

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

2 min

Dermatology

Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

2 min

Dermatology

Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.

expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

3 min

Dermatology

Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

2 min

Dermatology

Dr. Elmariah introduces the multiple roles of type 2 cytokines in chronic itch.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region